Analysts Set CareDx, Inc. (NASDAQ:CDNA) Target Price at $27.33

CareDx, Inc. (NASDAQ:CDNA) has earned an average rating of “Hold” from the nine ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $27.3333.

Several research firms recently weighed in on CDNA. Zacks Research upgraded shares of CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th. BTIG Research increased their target price on shares of CareDx from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings cut shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, February 27th. Wall Street Zen lowered CareDx from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, Wells Fargo & Company raised their target price on CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th.

Insider Buying and Selling

In other CareDx news, CEO John Walter Hanna, Jr. sold 19,280 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total transaction of $407,964.80. Following the sale, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at $12,641,089.80. This represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 29,636 shares of company stock worth $625,949 over the last quarter. 4.40% of the stock is owned by corporate insiders.

Institutional Trading of CareDx

A number of institutional investors have recently modified their holdings of CDNA. Bamco Inc. NY grew its stake in CareDx by 29.5% in the 3rd quarter. Bamco Inc. NY now owns 3,155,180 shares of the company’s stock valued at $45,876,000 after buying an additional 719,523 shares in the last quarter. State Street Corp boosted its holdings in shares of CareDx by 6.7% in the fourth quarter. State Street Corp now owns 2,737,752 shares of the company’s stock worth $51,579,000 after acquiring an additional 171,303 shares during the period. Deerfield Management Company L.P. purchased a new position in shares of CareDx in the third quarter valued at $31,857,000. Braidwell LP bought a new stake in shares of CareDx during the 3rd quarter valued at $31,738,000. Finally, ARK Investment Management LLC lifted its holdings in CareDx by 3.4% during the 3rd quarter. ARK Investment Management LLC now owns 2,170,625 shares of the company’s stock worth $31,561,000 after purchasing an additional 70,468 shares in the last quarter.

CareDx Stock Down 0.8%

CareDx stock opened at $17.74 on Friday. CareDx has a 52 week low of $10.96 and a 52 week high of $21.49. The company’s 50 day moving average price is $19.50 and its two-hundred day moving average price is $17.15. The stock has a market cap of $908.64 million, a P/E ratio of -44.35 and a beta of 2.52.

CareDx (NASDAQ:CDNA) last released its earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.12). CareDx had a negative net margin of 5.65% and a negative return on equity of 6.50%. The business had revenue of $108.39 million during the quarter, compared to the consensus estimate of $102.76 million. During the same period in the prior year, the company earned $0.18 earnings per share. The business’s revenue was up 25.2% on a year-over-year basis. On average, equities analysts anticipate that CareDx will post -0.9 EPS for the current year.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.